Cue Biopharma will discuss Immuno-STAT® advancements at the Cantor Global Healthcare Conference on September 5, 2025.
Quiver AI Summary
Cue Biopharma, Inc. announced its participation in the upcoming Cantor Global Healthcare Conference in New York from September 3-5, 2025, where CEO Daniel Passeri will lead a fireside chat on September 5, from 8:00 to 8:30 a.m. EDT. The discussion will focus on updates regarding their Immuno-STAT® platform and the development of CUE-401, the company’s primary asset for treating autoimmune disease. A live webcast of the event will be available, along with an archived version for 30 days on the company's website. Cue Biopharma specializes in creating innovative therapeutic biologics aimed at selectively targeting T cells to treat autoimmune diseases and cancer, leveraging their unique Immuno-STAT® technology.
Potential Positives
- Participation in the prestigious Cantor Global Healthcare Conference showcases Cue Biopharma's commitment to engaging with the healthcare community and investors.
- The opportunity to discuss program updates on the Immuno-STAT® platform emphasizes the ongoing advancements in Cue Biopharma's lead asset, CUE-401, highlighting the company's progress in innovative treatments for autoimmune diseases.
- The presence of the CEO, Daniel Passeri, at the event signals strong leadership and the company's dedication to transparent communication with stakeholders.
Potential Negatives
- Participation in the conference may imply the company is looking to raise investor interest due to potential challenges in gaining traction for its lead asset, CUE-401.
FAQ
What is Cue Biopharma's participation in the Cantor Global Healthcare Conference?
Cue Biopharma will engage in a fireside chat to discuss program updates on September 5, 2025.
Who will represent Cue Biopharma at the conference?
Daniel Passeri, the Chief Executive Officer, will present during the fireside chat.
What time will Cue Biopharma's presentation take place?
The fireside chat is scheduled for 8:00 a.m. to 8:30 a.m. EDT on September 5, 2025.
Where can I access the webcast of the presentation?
The webcast will be available on the Company's website under News and Events and archived for 30 days.
What is the focus of Cue Biopharma's Immuno-STAT® platform?
The Immuno-STAT® platform focuses on selectively engaging and modulating disease-specific T cells for autoimmune diseases and cancer treatment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CUE Hedge Fund Activity
We have seen 18 institutional investors add shares of $CUE stock to their portfolio, and 31 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GC WEALTH MANAGEMENT RIA, LLC added 3,331,644 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,273,180
- BLEICHROEDER LP added 1,821,924 shares (+36.5%) to their portfolio in Q2 2025, for an estimated $1,243,098
- VANGUARD GROUP INC added 871,484 shares (+37.6%) to their portfolio in Q2 2025, for an estimated $594,613
- GOOD LIFE ADVISORS, LLC removed 400,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $364,400
- SIGMA PLANNING CORP removed 270,760 shares (-83.0%) from their portfolio in Q2 2025, for an estimated $184,739
- UBS GROUP AG added 231,270 shares (+377.2%) to their portfolio in Q2 2025, for an estimated $157,795
- BLACKROCK, INC. removed 186,041 shares (-29.3%) from their portfolio in Q2 2025, for an estimated $126,935
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CUE Analyst Ratings
Wall Street analysts have issued reports on $CUE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens Capital Markets issued a "Market Outperform" rating on 04/02/2025
To track analyst ratings and price targets for $CUE, check out Quiver Quantitative's $CUE forecast page.
Full Release
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held in New York, September 3-5, 2025.
During the fireside chat, Cue Biopharma will discuss program updates from the Immuno-STAT ® platform including continued advancements in the development of CUE-401, the Company’s lead autoimmune asset.
Presentation Details
Cantor Global Healthcare Conference
Date:
Friday, September 5, 2025
Time:
8:00 a.m. – 8:30 a.m. EDT
Presenter:
Daniel Passeri, Chief Executive Officer
Webcast Link:
https://stream.onstreammedia.com/onsm/GetReport?customerId=22&eventId=15390931
A live and archived webcast of the fireside chat will be available under News and Events in the News and Publications section of the Company’s website . The webcast will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT
®
(Selective Targeting and Alteration of T cells)
, and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information, please visit www.cuebiopharma.com and follow us on X and LinkedIn .
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
[email protected]
Media Contact
Jonathan Pappas
LifeSci Communications
[email protected]
